chr2-227280930-A-AC
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000091.5(COL4A3):c.2417dupC(p.Gly807ArgfsTer28) variant causes a frameshift change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000106 in 1,412,300 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Likely pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_000091.5 frameshift
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD3 exomes AF: 0.00000578 AC: 1AN: 172936Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 92252
GnomAD4 exome AF: 0.0000106 AC: 15AN: 1412300Hom.: 0 Cov.: 31 AF XY: 0.0000100 AC XY: 7AN XY: 697912
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Autosomal recessive Alport syndrome Pathogenic:3
- -
- -
Variant summary: COL4A3 c.2417dupC (p.Gly807ArgfsX28) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory. The variant allele was found at a frequency of 5.8e-06 in 172936 control chromosomes. c.2417dupC has been reported in the literature in at least one individual affected with Alport Syndrome, Autosomal Recessive (Heidet_2001). To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Two clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic/likely pathogenic. Based on the evidence outlined above, the variant was classified as likely pathogenic. -
not provided Pathogenic:2
This sequence change creates a premature translational stop signal (p.Gly807Argfs*28) in the COL4A3 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in COL4A3 are known to be pathogenic (PMID: 8956999, 24854265, 26809805, 27281700). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with Alport syndrome (PMID: 11134255). ClinVar contains an entry for this variant (Variation ID: 552236). For these reasons, this variant has been classified as Pathogenic. -
Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 36117978, 37217505, 11134255, 38346493) -
COL4A3-related disorder Pathogenic:1
The COL4A3 c.2417dupC variant is predicted to result in a frameshift and premature protein termination (p.Gly807Argfs*28). This variant has been reported in the homozygous and compound heterozygous states in multiple individuals with Alport syndrome (Heidet et al. 2001. PubMed ID: 11134255; Table S1, Ćomić et al. 2022. PubMed ID: 36117978). This variant is reported in 0.0014% of alleles in individuals of European (non-Finnish) descent in gnomAD. Frameshift variants in COL4A3 are expected to be pathogenic. This variant is interpreted as pathogenic. -
Hematuria, benign familial, 2;C5882663:Autosomal dominant Alport syndrome;C5882699:Alport syndrome 3b, autosomal recessive Pathogenic:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at